Your Shopping Cart Is Empty
| Report Code: A03170 | Oct 2020 | Pages: 266 | ||
| Tables: 154 | Charts: 54 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Cephalosporin Market
Request Now !The global cephalosporin market size was valued at $13.69 billion in 2019, and is estimated to reach $16.87 Billion by 2027, growing at a CAGR of 2.6% from 2019 to 2027.
Cephalosporin is a bactericidal, broad-spectrum, and β-lactam antibiotic originally derived from fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, gonorrhea, and others. They inhibit enzymes in cell wall of susceptible bacteria, disrupting cell synthesis. Cephalosporins are mainly designated for prophylaxis as well as treatment of infections caused by bacteria. First-generation cephalosporins are active mainly against gram-positive bacteria, such as Streptococcus and Staphylococcus. Hence, they are used primarily for soft tissue and skin infections as well as to prevent from hospital-acquired surgical infections. Successive generations i.e. from second-generation to fifth generation of cephalosporins have increased activity against gram-negative bacteria and gram-positive organisms. Cephalosporin may be used for patients who are allergic to penicillin due to different β-lactam antibiotic structure.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19), a novel human coronavirus responsible for about 300,000 deaths worldwide. Till date, there is no confirmed treatment or vaccine prevention strategy against COVID-19. Hence, owing to urgent need for effective treatment, drug repurposing is regarded as the immediate option. Potential drugs can be identified via silico drug screening experiments. Thereby, in vitro and in vivo studies are going on to evaluate the potential of generations of cephalosporin for COVID-19.
The global cephalosporin market is experiencing growth, owing to surge in prevalence of infectious diseases, increase in R&D activities for development of combination drugs, and rise in funding for development of antibiotics. In addition, rise in demand for antibacterial drugs further drives growth of the global cephalosporin market. However, side effects associated with cephalosporin, uncertain regulatory reforms, antibiotic resistance to cephalosporin, and less drugs in pipeline are projected to impede the cephalosporin market growth. On the contrary, discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer remunerative opportunities for the market players.
The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. On the basis of generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generic. Depending on route of administration, it is classified into intravenous and oral. Applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
On the basis of generation, the third-generation cephalosporin segment generated the highest revenue in 2019, and is anticipated to maintain its dominance throughout the forecast period, as these are used for treatment of gram-negative bacillary meningitis, serious infections of enterobacteriaceae, otitis media, pyelonephritis, skin & soft tissue infections, Lyme disease, and gonorrhea. However, the fifth-generation cephalosporin segment is expected to register highest CAGR during the forecast period, as these drugs possess strong activity against aerobic gram-negative bacteria and exceptional activity against aerobic gram-positive bacteria.
By type, the generic cephalosporin drugs segment is projected to exhibit highest growth during the forecast period, as these drugs are available at a much lower cost as compared to branded drugs. Moreover, pharmacological effects of generic drugs are exactly same as those of their brand-name counterparts.
Region wise, the antibiotics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific dominated the market in 2019, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to increase in consumption of cephalosporin, easier availability, and rise in demand for over-the-counter drugs, and increase in bacterial infection in the region.
The report provides a comprehensive analysis of the key players operating in the global cephalosporin industry, namely, Allergan Plc., Bristol-Myers Squibb Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Limited (Lupin Pharmaceuticals, Inc.), Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Eli Lilly and Company, Bayer HealthCare, Sun Pharmaceutical, and Shionogi.
Key Benefits For Stakeholders
Cephalosporin Market Report Highlights
| Aspects | Details |
|---|---|
| By Generation |
|
| By Type |
|
| By Route Of Administration |
|
| By Application |
|
| By Region |
|
| Key Market Players | SANOFI, ABBVIE INC. (ALLERGAN PLC.), PFIZER INC., MERCK & CO., INC., LUPIN LIMITED (LUPIN PHARMACEUTICALS, INC.), NOVARTIS INTERNATIONAL AG (SANDOZ), F. HOFFMANN-LA ROCHE LTD., GLAXOSMITHKLINE PLC, TEVA PHARMACEUTICAL INDUSTRIES LTD., BRISTOL-MYERS SQUIBB COMPANY |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Top winning strategies
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Surge in incidences of infectious diseases
3.4.1.2.Increase in R&D activities for development of combination drugs
3.4.1.3.Rise in funding for development of antibiotics
3.4.2.Restraints
3.4.2.1.Side effects associated with cephalosporin
3.4.2.2.Antibiotic resistance to cephalosporin
3.4.3.Opportunities
3.4.3.1.Lucrative opportunities in emerging economies
3.5.Market share analysis, 2019
3.6.Porter’s five forces analysis
3.7.Impact analysis of COVID-19 on cephalosporin market
CHAPTER 4:CEPHALOSPORIN MARKET, BY GENERATION
4.1.Overview
4.1.1.Market size and forecast
4.2.First-generation cephalosporin
4.2.1.Key market trends and growth opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Second-generation cephalosporin
4.3.1.Key market trends and growth opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.4.Third-generation cephalosporin
4.4.1.Key market trends and growth opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country
4.5.Fourth-generation cephalosporin
4.5.1.Key market trends and growth opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country
4.6.Fifth-generation cephalosporin
4.6.1.Key market trends and growth opportunities
4.6.2.Market size and forecast
4.6.3.Market analysis, by country
CHAPTER 5:CEPHALOSPORIN MARKET, BY TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Branded
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Generic
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
CHAPTER 6:CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Intravenous
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Oral
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
CHAPTER 7:CEPHALOSPORIN MARKET, BY APPLICATION
7.1.Overview
7.1.1.Market size and forecast
7.2.Respiratory tract infection
7.2.1.Market size and forecast
7.2.2.Market analysis, by country
7.3.Skin infection
7.3.1.Market size and forecast
7.3.2.Market analysis, by country
7.4.Ear infection
7.4.1.Market size and forecast
7.4.2.Market analysis, by country
7.5.Urinary tract infection
7.5.1.Market size and forecast
7.5.2.Market analysis, by country
7.6.Sexually transmitted infection
7.6.1.Market size and forecast
7.6.2.Market analysis, by country
7.7.Others
7.7.1.Market size and forecast
7.7.2.Market analysis, by country
CHAPTER 8:CEPHALOSPORIN MARKET, BY REGION
8.1.Overview
8.1.1.Market size and forecast
8.2.North America
8.2.1.Key market trends and growth opportunities
8.2.2.North America cephalosporin market, by country
8.2.2.1.U.S. cephalosporin market, by generation
8.2.2.2.U.S. cephalosporin market, by type
8.2.2.3.U.S. cephalosporin market, by route of administration
8.2.2.4.U.S. cephalosporin market, by application
8.2.2.5.Canada cephalosporin market, by generation
8.2.2.6.Canada cephalosporin market, by type
8.2.2.7.Canada cephalosporin market, by route of administration
8.2.2.8.Canada cephalosporin market, by application
8.2.2.9.Mexico cephalosporin market, by generation
8.2.2.10.Mexico cephalosporin market, by type
8.2.2.11.Mexico cephalosporin market, by route of administration
8.2.2.12.Mexico cephalosporin market, by application
8.2.3.North America cephalosporin market, by generation
8.2.4.North America cephalosporin market, by type
8.2.5.North America cephalosporin market, by route of administration
8.2.6.North America cephalosporin market, by application
8.3.Europe
8.3.1.Key market trends and growth opportunities
8.3.2.Europe cephalosporin market, by country
8.3.2.1.Germany cephalosporin market, by generation
8.3.2.2.Germany cephalosporin market, by type
8.3.2.3.Germany cephalosporin market, by route of administration
8.3.2.4.Germany cephalosporin market, by application
8.3.2.5.France cephalosporin market, by generation
8.3.2.6.France cephalosporin market, by type
8.3.2.7.France cephalosporin market, by route of administration
8.3.2.8.France cephalosporin market, by application
8.3.2.9.UK cephalosporin market, by generation
8.3.2.10.UK cephalosporin market, by type
8.3.2.11.UK cephalosporin market, by route of administration
8.3.2.12.UK cephalosporin market, by application
8.3.2.13.Italy cephalosporin market, by generation
8.3.2.14.Italy cephalosporin market, by type
8.3.2.15.Italy cephalosporin market, by route of administration
8.3.2.16.Italy cephalosporin market, by application
8.3.2.17.Spain cephalosporin market, by generation
8.3.2.18.Spain cephalosporin market, by type
8.3.2.19.Spain cephalosporin market, by route of administration
8.3.2.20.Spain cephalosporin market, by application
8.3.2.21.Rest of Europe cephalosporin market, by generation
8.3.2.22.Rest of Europe cephalosporin market, by type
8.3.2.23.Rest of Europe cephalosporin market, by route of administration
8.3.2.24.Rest of Europe cephalosporin market, by application
8.3.3.Europe cephalosporin market, by generation
8.3.4.Europe cephalosporin market, by type
8.3.5.Europe cephalosporin market, by route of administration
8.3.6.Europe cephalosporin market, by application
8.4.Asia-Pacific
8.4.1.Key market trends and growth opportunities
8.4.2.Asia-Pacific cephalosporin market, by country
8.4.2.1.Japan cephalosporin market, by generation
8.4.2.2.Japan cephalosporin market, by type
8.4.2.3.Japan cephalosporin market, by route of administration
8.4.2.4.Japan cephalosporin market, by application
8.4.2.5.China cephalosporin market, by generation
8.4.2.6.China cephalosporin market, by type
8.4.2.7.China cephalosporin market, by route of administration
8.4.2.8.China cephalosporin market, by application
8.4.2.9.India cephalosporin market, by generation
8.4.2.10.India cephalosporin market, by type
8.4.2.11.India cephalosporin market, by route of administration
8.4.2.12.India cephalosporin market, by application
8.4.2.13.Australia cephalosporin market, by generation
8.4.2.14.Australia cephalosporin market, by type
8.4.2.15.Australia cephalosporin market, by route of administration
8.4.2.16.Australia cephalosporin market, by application
8.4.2.17.Rest of Asia-Pacific cephalosporin market, by generation
8.4.2.18.Rest of Asia-Pacific cephalosporin market, by type
8.4.2.19.Rest of Asia-Pacific cephalosporin market, by route of administration
8.4.2.20.Rest of Asia-Pacific cephalosporin market, by application
8.4.3.Asia-Pacific cephalosporin market, by generation
8.4.4.Asia-Pacific cephalosporin market, by type
8.4.5.Asia-Pacific cephalosporin market, by route of administration
8.4.6.Asia-Pacific cephalosporin market, by application
8.5.LAMEA
8.5.1.Key market trends and growth opportunities
8.5.2.LAMEA cephalosporin market, by country
8.5.2.1.Brazil cephalosporin market, by generation
8.5.2.2.Brazil cephalosporin market, by type
8.5.2.3.Brazil cephalosporin market, by route of administration
8.5.2.4.Brazil cephalosporin market, by application
8.5.2.5.South Africa cephalosporin market, by generation
8.5.2.6.South Africa cephalosporin market, by type
8.5.2.7.South Africa cephalosporin market, by route of administration
8.5.2.8.South Africa cephalosporin market, by application
8.5.2.9.Saudi Arabia cephalosporin market, by generation
8.5.2.10.Saudi Arabia cephalosporin market, by type
8.5.2.11.Saudi Arabia cephalosporin market, by route of administration
8.5.2.12.Saudi Arabia cephalosporin market, by application
8.5.2.13.Rest of LAMEA cephalosporin market, by generation
8.5.2.14.Rest of LAMEA cephalosporin market, by type
8.5.2.15.Rest of LAMEA cephalosporin market, by route of administration
8.5.2.16.Rest of LAMEA cephalosporin market, by application
8.5.3.LAMEA cephalosporin market, by generation
8.5.4.LAMEA cephalosporin market, by type
8.5.5.LAMEA cephalosporin market, by route of administration
8.5.6.LAMEA cephalosporin market, by application
CHAPTER 9:COMPANY PROFILES
9.1.ABBVIE INC. (ALLERGAN PLC.)
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments
9.2.BRISTOL-MYERS SQUIBB COMPANY
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segment
9.2.4.Product portfolio
9.2.5.Business performance
9.3.F. HOFFMANN-LA ROCHE LTD.
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.3.6.Key strategic moves and developments
9.4.GLAXOSMITHKLINE PLC
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.5.LUPIN LIMITED (LUPIN PHARMACEUTICALS, INC.)
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance
9.6.MERCK & CO., INC.
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.6.6.Key strategic moves and developments
9.7.NOVARTIS INTERNATIONAL AG (SANDOZ)
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance
9.8.PFIZER INC.
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.8.6.Key strategic moves and developments
9.9.SANOFI
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.9.6.Key strategic moves and developments
9.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
LIST OF TABLES
TABLE 01.CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 02.FIRST-GENERATION CEPHALOSPORIN
TABLE 03.FIRST-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 04.SECOND-GENERATION CEPHALOSPORIN
TABLE 05.SECOND-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.THIRD-GENERATION CEPHALOSPORIN
TABLE 07.THIRD-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 08.FOURTH-GENERATION CEPHALOSPORIN
TABLE 09.FOURTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 10.FIFTH-GENERATION CEPHALOSPORIN
TABLE 11.FIFTH-GENERATION CEPHALOSPORIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 12.CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 13.BRANDED CEPHALOSPORIN DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 14.GENERIC CEPHALOSPORIN DRUGS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 15.CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 16.CEPHALOSPORIN DRUGS THAT ARE GIVEN AS INTRAVENOUS
TABLE 17.INTRAVENOUS CEPHALOSPORIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 18.ORAL CEPHALOSPORIN DRUGS
TABLE 19.ORAL CEPHALOSPORIN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 20.CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 21.CEPHALOSPORIN DRUGS USED TO TREAT RESPIRATORY TRACT INFECTION
TABLE 22.CEPHALOSPORIN MARKET FOR RESPIRATORY TRACT INFECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 23.CEPHALOSPORIN DRUGS USED TO TREAT SKIN INFECTION
TABLE 24.CEPHALOSPORIN MARKET FOR SKIN INFECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 25.CEPHALOSPORIN DRUGS USED TO TREAT EAR INFECTION
TABLE 26.CEPHALOSPORIN MARKET FOR EAR INFECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 27.CEPHALOSPORIN DRUGS USED TO TREAT URINARY TRACT INFECTION
TABLE 28.CEPHALOSPORIN MARKET FOR URINARY TRACT INFECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 29.CEPHALOSPORIN DRUGS USED TO TREAT INFECTION CAUSED DUE TO GONORRHEA
TABLE 30.CEPHALOSPORIN MARKET FOR SEXUALLY TRANSMITTED INFECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 31.CEPHALOSPORIN DRUGS USED FOR OTHER APPLICATIONS
TABLE 32.CEPHALOSPORIN MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 33.CEPHALOSPORIN MARKET, BY REGION ($MILLION), 2019–2027
TABLE 34.NORTH AMERICA CEPHALOSPORIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 35.U.S. CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 36.U.S. CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 37.U.S. CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 38.U.S. CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 39.CANADA CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 40.CANADA CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 41.CANADA CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 42.CANADA CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 43.MEXICO CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 44.MEXICO CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 45.MEXICO CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 46.MEXICO CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 47.NORTH AMERICA CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 48.NORTH AMERICA CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 49.NORTH AMERICA CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 50.NORTH AMERICA CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 51.EUROPE CEPHALOSPORIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 52.GERMANY CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 53.GERMANY CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 54.GERMANY CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 55.GERMANY CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 56.FRANCE CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 57.FRANCE CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 58.FRANCE CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 59.FRANCE CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 60.UK CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 61.UK CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 62.UK CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 63.UK CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 64.ITALY CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 65.ITALY CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 66.ITALY CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 67.ITALY CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 68.SPAIN CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 69.SPAIN CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 70.SPAIN CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 71.SPAIN CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 72.REST OF EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 73.REST OF EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 74.REST OF EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 75.REST OF EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 76.EUROPE CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 77.EUROPE CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 78.EUROPE CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 79.EUROPE CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 80.ASIA-PACIFIC CEPHALOSPORIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 81.JAPAN CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 82.JAPAN CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 83.JAPAN CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 84.JAPAN CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 85.CHINA CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 86.CHINA CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 87.CHINA CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 88.CHINA CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 89.INDIA CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 90.INDIA CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 91.INDIA CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 92.INDIA CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 93.AUSTRALIA CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 94.AUSTRALIA CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 95.AUSTRALIA CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 96.AUSTRALIA CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 97.REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 98.REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 99.REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 100.REST OF ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 101.ASIA-PACIFIC CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 102.ASIA-PACIFIC CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 103.ASIA-PACIFIC CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 104.ASIA-PACIFIC CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 105.LAMEA CEPHALOSPORIN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 106.BRAZIL CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 107.BRAZIL CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 108.BRAZIL CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 109.BRAZIL CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 110.SOUTH AFRICA CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 111.SOUTH AFRICA CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 112.SOUTH AFRICA CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 113.SOUTH AFRICA CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 114.SAUDI ARABIA CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 115.SAUDI ARABIA CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 116.SAUDI ARABIA CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 117.SAUDI ARABIA CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 118.REST OF LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 119.REST OF LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 120.REST OF LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 121.REST OF LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 122.LAMEA CEPHALOSPORIN MARKET, BY GENERATION, 2019–2027 ($MILLION)
TABLE 123.LAMEA CEPHALOSPORIN MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 124.LAMEA CEPHALOSPORIN MARKET, BY ROUTE OF ADMINISTRATION, 2019–2027 ($MILLION)
TABLE 125.LAMEA CEPHALOSPORIN MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 126.ABBVIE: COMPANY SNAPSHOT
TABLE 127.ABBVIE: OPERATING SEGMENTS
TABLE 128.ALLERGAN: PRODUCT PORTFOLIO
TABLE 129.BMS: COMPANY SNAPSHOT
TABLE 130.BMS: PRODUCT PORTFOLIO
TABLE 131.ROCHE: COMPANY SNAPSHOT
TABLE 132.ROCHE: OERATING SEGMENT
TABLE 133.ROCHE: PRODUCT PORTFOLIO
TABLE 134.GSK: COMPANY SNAPSHOT
TABLE 135.GSK: OPERATING SEGMENTS
TABLE 136.GSK: PRODUCT PORTFOLIO
TABLE 137.LUPIN LIMITED: COMPANY SNAPSHOT
TABLE 138.LUPIN LIMITED: OPERATING SEGMENTS
TABLE 139.LUPIN LIMITED: PRODUCT PORTFOLIO
TABLE 140.MERCK: COMPANY SNAPSHOT
TABLE 141.MERCK: OPERATING SEGMENTS
TABLE 142.MERCK: PRODUCT PORTFOLIO
TABLE 143.NOVARTIS: COMPANY SNAPSHOT
TABLE 144.NOVARTIS: OPERATING SEGMENTS
TABLE 145.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 146.PFIZER: COMPANY SNAPSHOT
TABLE 147.PFIZER: OPERATING SEGMENTS
TABLE 148.PFIZER: PRODUCT PORTFOLIO
TABLE 149.SANOFI: COMPANY SNAPSHOT
TABLE 150.SANOFI: OPERATING SEGMENTS
TABLE 151.SANOFI: PRODUCT PORTFOLIO
TABLE 152.TEVA: COMPANY SNAPSHOT
TABLE 153.TEVA: OPERATING SEGMENTS
TABLE 154.TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.CEPHALOSPORIN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2020*
FIGURE 06.MARKET SHARE ANALYSIS, 2019
FIGURE 07.LOW BARGAINING POWER OF BUYERS
FIGURE 08.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 09.HIGH THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANT
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR FIRST-GENERATION CEPHALOSPORIN, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR SECOND-GENERATION CEPHALOSPORIN, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR THIRD-GENERATION CEPHALOSPORIN, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR FOURTH-GENERATION CEPHALOSPORIN, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR FIFTH-GENERATION CEPHALOSPORIN, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR BRANDED, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR GENERIC, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR INTRAVENOUSS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR ORAL, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR RESPIRATORY TRACT INFECTION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR SKIN INFECTION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR EAR INFECTION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR URINARY TRACT INFECTION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR SEXUALLY TRANSMITTED INFECTION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF CEPHALOSPORIN MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 27.ABBVIE: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.ABBVIE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 29.ABBVIE: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 30.BMS: NET SALES, 2017–2019 ($MILLION)
FIGURE 31.BMS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 32.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 34.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 35.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 36.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 37.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 38.LUPIN LIMITED: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.LUPIN LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 43.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 45.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 46.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 47.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 48.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 49.SANOFI: NET SALES, 2017–2019 ($MILLION)
FIGURE 50.SANOFI: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 51.SANOFI: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 52.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 53.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 54.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
Rise in global prevalence of pneumonia, tonsillitis, bronchitis, and gonorrhea constitutes a major proportion of health and economic burden. Therefore, the adoption of cephalosporin is expected to increase in the near future. Moreover, increase in R&D activities for the development of combination drugs and rise in funding for the development of antibiotics further drives the market growth. Fifth-generation and fourth-generation of cephalosporin are expected to provide lucrative opportunities to market players, owing to the surge in prevalence of bacterial infectious diseases and increasing antimicrobial resistance.
Asia-Pacific is expected to grow at the highest CAGR during the study period. This is attributable to easy obtainability of cephalosporin over the counter and no obligation on their usage in this region. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to high prevalence of infectious diseases and rise in demand for cephalosporin.
A. The market value of Global Cephalosporin market was $13.69 billion in 2019.
A. The forecast period is from 2019 to 2027.
A. The market value of Global Cephalosporin market in 2020 is $14.86 billion.
A. The Global Cephalosporin market is expected to exhibit significant growth during the forecast period, owing to surge in prevalence of infectious diseases, increase in R&D activities for development of combination drugs, and rise in funding for development of antibiotics
A. The base year is 2019 in Global Cephalosporin market
A. Based on generation, the third-generation cephalosporin segment held a major share in the Global Cephalosporin market in 2019 and is expected to continue the trend in the forecasting period.
Start reading instantly.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report